Institution
University of North Texas Health Science Center
Education•Fort Worth, Texas, United States•
About: University of North Texas Health Science Center is a education organization based out in Fort Worth, Texas, United States. It is known for research contribution in the topics: Population & Receptor. The organization has 2972 authors who have published 5401 publications receiving 153180 citations. The organization is also known as: UNT Health Science Center & UNTHSC.
Topics: Population, Receptor, Health care, Neuroprotection, Cancer
Papers published on a yearly basis
Papers
More filters
••
TL;DR: The discovery of potent, selective and bioavailable D( 3) receptor ligands will provide essential molecular probes to elucidate the role D(3) receptors play in the psychomotor stimulant and reinforcing effects of cocaine.
63 citations
•
TL;DR: Inhibition of GSK-3β activity by the G SK-3 β inhibitor SB216763 provides positive protection against mitochondrial depolarization, as demonstrated with JC-1 fluorescent dye analysis.
Abstract: Purpose
Dissipation of the electrochemical gradient across the inner mitochondrial membrane results in mitochondrial membrane permeability transition (mMPT), a potential early marker for the onset of apoptosis. In this study, we demonstrate a role for glycogen synthase kinase-3β (GSK-3β) in regulating mMPT. Using direct inhibition of GSK-3β with the GSK-3β inhibitor SB216763, mitochondria may be prevented from depolarizing (hereafter referred to as mitoprotection). Cells treated with SB216763 showed an artifact of fluorescence similar to the green emission spectrum of the JC-1 dye. We demonstrate the novel use of spectral deconvolution to negate the interfering contributing fluorescence by SB216763, thus allowing an unfettered analysis of the JC-1 dye to determine the mitochondrial membrane potential.
63 citations
••
TL;DR: Elevated intraocular pressure mediated increase in ETB receptor expression and its activation may contribute to a decrease in RGC survival as seen in glaucoma, raising the possibility of using endothelin receptor antagonists as neuroprotective agents for the treatment of glAUcoma.
Abstract: Glaucoma is an optic neuropathy, commonly associated with elevated intraocular pressure (IOP) characterized by optic nerve degeneration, cupping of the optic disc, and loss of retinal ganglion cells which could lead to loss of vision. Endothelin-1 (ET-1) is a 21-amino acid vasoactive peptide that plays a key role in the pathogenesis of glaucoma; however, the receptors mediating these effects have not been defined. In the current study, endothelin B (ETB) receptor expression was assessed in vivo, in the Morrison's ocular hypertension model of glaucoma in rats. Elevation of IOP in Brown Norway rats produced increased expression of ETB receptors in the retina, mainly in retinal ganglion cells (RGCs), nerve fiber layer (NFL), and also in the inner plexiform layer (IPL) and inner nuclear layer (INL). To determine the role of ETB receptors in neurodegeneration, Wistar-Kyoto wild type (WT) and ETB receptor-deficient (KO) rats were subjected to retrograde labeling with Fluoro-Gold (FG), following which IOP was elevated in one eye while the contralateral eye served as control. IOP elevation for 4 weeks in WT rats caused an appreciable loss of RGCs, which was significantly attenuated in KO rats. In addition, degenerative changes in the optic nerve were greatly reduced in KO rats compared to those in WT rats. Taken together, elevated intraocular pressure mediated increase in ETB receptor expression and its activation may contribute to a decrease in RGC survival as seen in glaucoma. These findings raise the possibility of using endothelin receptor antagonists as neuroprotective agents for the treatment of glaucoma.
63 citations
••
TL;DR: The results indicate that AR regulates cancer cell adhesion, invasion and migration events which initiate metastasis and therefore, AR inhibition could be a novel therapeutic approach for the prevention of colon cancer metastasis.
Abstract: Colon cancer is the third most common cause of cancer and is the second leading cause of cancer deaths in the USA. Although inhibition of aldose reductase (AR) is known to prevent human colon cancer cell growth in nude mice xenografts, the role of AR in the regulation of cancer metastasis is not known. We now demonstrate the mechanisms by which AR regulates colon cancer metastasis in vitro and in vivo. Inhibition of AR prevented the epidermal growth factor (EGF) or fibroblast growth factor (FGF)-induced migration and invasion of human colon cancer (HT29; KM20) cells by >70% and also inhibited (>80%) the adhesion of the cancer cells to endothelial cells. Treatment of endothelial cells with AR inhibitors significantly (� 85%) downregulated the EGF or FGF-induced expression of Inter-Cellular Adhesion Molecule-1, Vascular cell adhesion molecule-1 and vascular endothelial-cadherin. Furthermore, liver metastasis of green fluorescent protein-labeled KM20 cells injected into the spleen of athymic nude mice was significantly (>65%) prevented by AR inhibitor, fidarestat or ARsiRNA delivered systemically into the mice. Similar results were observed with HT29 cells. AR inhibition or ablation also prevented (70‐90%) the increase in the levels of matrix metalloproteinase-2, cyclin D1, CD31, CD34 and the activation of nuclear factor-kappa-binding protein in metastatic liver. Thus, our results indicate that AR regulates cancer cell adhesion, invasion and migration events which initiate metastasis and therefore, AR inhibition could be a novel therapeutic approach for the prevention of colon cancer metastasis.
62 citations
•
31 Oct 2002TL;DR: In this article, the authors present methods for identifying an agent useful for the treatment of glaucoma using an agent-based approach based on an agent classifier. But this method is not suitable for blind individuals.
Abstract: The present invention provides methods for identifying an agent useful for the treatment of glaucoma.
62 citations
Authors
Showing all 3001 results
Name | H-index | Papers | Citations |
---|---|---|---|
John T. Potts | 90 | 359 | 29359 |
Evan A. Stein | 80 | 340 | 36392 |
James W. Simpkins | 79 | 431 | 20574 |
Robert J. Gatchel | 79 | 494 | 25583 |
Douglas B. Cines | 79 | 397 | 27792 |
Ranajit Chakraborty | 77 | 407 | 25474 |
Kunlin Jin | 75 | 258 | 23282 |
Bruce Budowle | 70 | 613 | 20227 |
Lisa L. Barnes | 69 | 280 | 20190 |
Abbot F. Clark | 65 | 297 | 13938 |
Yong Fang Kuo | 65 | 447 | 14938 |
Alexander C. Wagenaar | 63 | 241 | 13661 |
David P. Siderovski | 62 | 180 | 19698 |
Yogesh C. Awasthi | 61 | 254 | 12304 |
Ignacy Gryczynski | 61 | 545 | 16705 |